These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 25944695

  • 1. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 2. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.
    Int J Cancer; 2018 Jan 01; 142(1):202-213. PubMed ID: 28905990
    [Abstract] [Full Text] [Related]

  • 3. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
    Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J, Deng X.
    Br J Pharmacol; 2019 Dec 01; 176(23):4491-4509. PubMed ID: 31364164
    [Abstract] [Full Text] [Related]

  • 4. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
    Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.
    Br J Haematol; 2014 Jul 01; 166(2):177-88. PubMed ID: 24697238
    [Abstract] [Full Text] [Related]

  • 5. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S, Dammeijer F, Hendriks RW.
    Mol Cancer; 2018 Feb 19; 17(1):57. PubMed ID: 29455639
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.
    Int J Cancer; 2015 Jun 15; 136(12):2761-74. PubMed ID: 25388373
    [Abstract] [Full Text] [Related]

  • 7. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
    Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z.
    J Med Chem; 2014 Jun 26; 57(12):5112-28. PubMed ID: 24915291
    [Abstract] [Full Text] [Related]

  • 8. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
    Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF.
    Oncotarget; 2014 Jul 15; 5(13):4990-5001. PubMed ID: 24970801
    [Abstract] [Full Text] [Related]

  • 9. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.
    Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA.
    Blood; 2017 Mar 02; 129(9):1155-1165. PubMed ID: 28031181
    [Abstract] [Full Text] [Related]

  • 10. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J.
    Oncotarget; 2017 Jun 13; 8(24):39218-39229. PubMed ID: 28424405
    [Abstract] [Full Text] [Related]

  • 11. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.
    Proc Natl Acad Sci U S A; 2010 Jul 20; 107(29):13075-80. PubMed ID: 20615965
    [Abstract] [Full Text] [Related]

  • 12. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.
    Blood; 2011 Jun 09; 117(23):6287-96. PubMed ID: 21422473
    [Abstract] [Full Text] [Related]

  • 13. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep 09; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 14. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S.
    Leuk Res; 2013 Oct 09; 37(10):1271-7. PubMed ID: 23962569
    [Abstract] [Full Text] [Related]

  • 15. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D.
    Oncotarget; 2015 Dec 08; 6(39):42232-42. PubMed ID: 26540570
    [Abstract] [Full Text] [Related]

  • 16. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M.
    Mol Cancer Ther; 2019 Feb 08; 18(2):267-277. PubMed ID: 30413649
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.